Mycobacteria tuberculosis peritonitis associated with etanercept therapy.
Manadan
A M
AM
Block
J A
JA
Sequeira
W
W
D000328:Adult; D000995:Antitubercular Agents / Q000627:therapeutic use; D001171:Arthritis, Juvenile / Q000175:diagnosis / Q000188:drug therapy*; D001707:Biopsy, Needle; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D000068800:Etanercept; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016867:Immunocompromised Host; D007074:Immunoglobulin G / Q000009:adverse effects* / Q000627:therapeutic use; D007150:Immunohistochemistry; D009169:Mycobacterium tuberculosis / Q000302:isolation & purification*; D010538:Peritonitis / Q000188:drug therapy / Q000276:immunology / Q000382:microbiology*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D018570:Risk Assessment; D016896:Treatment Outcome; D014385:Tuberculosis, Gastrointestinal / Q000175:diagnosis* / Q000188:drug therapy / Q000276:immunology
D000995:Antitubercular Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept